Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness

Biological Psychiatry

Volumn 42, Issue 5, 1997, Pages 349-358

  Maes, Michael ^a,b,e   Vandoolaeghe, Eric ^a   Neels, Hugo ^c   Demedts, Paul ^c   Wauters, Annick ^c   Meltzer, Herbert Y ^b   Altamura, Carlo ^d   Desnyder, Roger ^a  

^a Stuivenberg General Hospital   (Belgium)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Laboratory of Clinical Biology   (Belgium)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e Clinical Research Center for Mental Health of Antwerp   (Belgium)

Author keywords

Acute phase proteins; Cell mediated immunity; Cytokines; Depression; T helper cells; Zinc

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; ANTIDEPRESSANT AGENT; BUSPIRONE; COPPER; DOSULEPIN; DOXEPIN; IMIPRAMINE; LIOTHYRONINE; LITHIUM; LOFEPRAMINE; MAPROTILINE; MIANSERIN; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TRANSFERRIN; ZINC;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HELPER CELL; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; ZINC BLOOD LEVEL;

ADULT; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; CD4-CD8 RATIO; COPPER; DEPRESSIVE DISORDER; DRUG RESISTANCE; FEMALE; HUMANS; INFLAMMATION; MALE; PSYCHIATRIC STATUS RATING SCALES; ZINC;

EID: 0030880731     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00365-4     Document Type: Article

References (61)

1. Aggett J, Harris JT (1979): Current status of zinc in health and disease. Arch Dis Child 54:909-917.
2. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press.
3. Arborelius L, Nomikos GG, Grillner P, et al (1995): 5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn Schiedebergs Arch Pharmacol 352:157-165.
4. Bremner I, Beattie JH (1995): Copper and zinc metabolism in health and disease: Speciation and interactions. Proc Nutr Soc 54:489-499.
5. Clabrese JR, Skwerer RG, Barna B, et al (1986): Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res 17:41-47.
6. Cousins RJ (1989): Systemic transport of zinc. In Mills CF (ed), Zinc in Human Biology. London: Springer-Verlag, pp 79-93.
7. Cousins RJ, Leinart AS (1988): Tissue-specific regulation of zinc metabolism and metallothionein genes by interleukin-1. FASEB J 2:2884-2890.
8. Couturier E, Praet JP, Vis HL, et al (1987): The increase in zincaemia provoked by starvation does not influence the intestinal absorption of zinc. Clin Chim Acta 163:165-169.
9. Duch DS, Woolf JH, Nichol CA, Davidson JR, Garbutt JC (1984): Urinary excretion of biopterin and neopterin in psychiatric disorders. Psychiatry Res 11:83-89.
10. Dunbar PR, Hill J, Neale TJ, Mellsop GW (1992): Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. Psychol Med 22:1051-1057.
11. Dunn MA, Cousins RJ (1989): Kinetics of zinc metabolism in the rat: Effect of dibutyryl cAMP. Am J Physiol 256:420-430.
12. Goode HF, Robertson DAF, Kelleher J, et al (1991): Effects of fasting, self-selected and isocaloric glucose and fat meals and intravenous feeding on plasma zinc concentrations. Ann Clin Biochem 28:442-445.
13. Grandjean P, Nielsen GD, Jorgensen PJ, et al (1992): Reference intervals for trace elements in blood: Significance of risk factors. Scand J Clin Lab Invest 52:321-337.
14. Hamilton M (1960): A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-61.
15. Hamilton M (1969): Diagnosis and rating of anxiety. Br J Psychiatry 3:76-79.
16. Hansen CR Jr, Malecha M, Mackenzie TB, Kroll J (1983): Copper and zinc deficiencies in association with depression and neurological findings Biol Psychiatry 18:395-401.
17. Howell DC (1982): Multiple comparisons among treatment means. In Howell DC (ed), Statistical Methods for Psychology. Boston: Duxbury Press, pp 289-307.
18. Joyce PR, Hawes CR, Mulder RT, Sellman JD, Wilson DA, Boswell DR (1992): Elevated levels of acute phase plasma proteins in major depression. Biol Psychiatry 32:1035-1041.
19. Kent S, Bluthé R-M, Kelley KW, Dantzer R (1992): Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13:24-28.
20. Lieb J, Karmali R (1983): Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med 10:361-368.
21. Linnoila M, Whorton R, Rubinow DR, Cowdry RW, Ninan PT, Waters RN (1983): CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry 40:405-406.
22. Lowe NM, Bremner I, Jackson MJ (1991): Plasma 65Zn kinetics in the rat. Br J Nutr 65:445-455.
23. Lowik MRH, Schrijver J, Odink J, et al (1990): Nutrition and aging: Nutritional status of apparently healthy elderly (Dutch Nutrition Surveillance System). J Am Coll Nutr 9:18-27.
24. Maes M (1995): Evidence for an immune response in major depression: A review and hypothesis. Prog Psychopharmacol Biol Psychiatry 19:11-38.
25. Maes M, Bosnians E, Suy E, et al (1991a): Depression-related disturbances in mitogen-induced lymphocyte responses, interleukin-1β, and soluble interleukin-2-receptor production. Acta Psychiatr Scand 84:379-386.
26. Maes M, Vandewoude M, Scharpé S, et al (1991b): Anthropometric and biochemical assessment of the nutritional state in depression: Evidence for lower visceral protein plasma levels in depression. J Affect Disord 23:25-33.
27. Maes M, Lambrechts J, Bosmans E, et al (1992a): Evidence for a systemic immune activation during depression: Results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 22:45-53.
28. Maes M, Scharpé S, Bosmans E, et al (1992b): Disturbances in acute phase plasma proteins during melancholia: Additional evidence for the presence of an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry 16:501-515.
29. Maes M, Scharpé S, Vamn Grootel L, et al (1992c): Higher α1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: Further evidence for the existence of an inflammatory response during that illness. J Affect Disord 24:183-192.
30. Maes M, Meltzer HY, Scharpé S, et al (1993a): Psychomotor retardation, anorexia, weight loss, sleep disturbances and loss of energy: Psychopathological correlates of hyperhaptoglobinemia during major depression. Psychiatry Res 47:229-241.
31. Maes M, Scharpé S, Meltzer HY, et al (1993b): Relationships between interleukin-6 activity, acute phase proteins and HPA-axis function in severe depression. Psychiatry Res 49:11-27.
32. Maes M, Scharpé S, Meltzer HY, Cosyns P (1993c): Relationships between increased haptoglobin plasma levels and activity of cell-mediated immunity. Biol Psychiatry 34:690-701.
33. Maes M, Scharpé S, D'Haese W, De Broe M, Cosyns P (1994a): Hypozincaemia in depression J Affect Disord 31:135-140.
34. Maes M, Scharpé S, Meltzer HY, Okayli G, D'Hondt P, Cosyns P (1994b): Increased neopterin and interferon gamma secretion and lower L-tryptophan levels in major depression: Further evidence for immune activation in severe depression. Psychiatry Res 54:143-160.
35. Maes M, Meltzer HY, Bosmans E, et al (1995a): Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 34:301-309.
36. Maes M, Scharpé S, Neels H, Wauters A, Van Gastel A, Cosyns P (1995b): Total serum protein and serum protein fractions in major depression. J Affect Disord 34:61-69.
37. McLoughlin IJ, Hodge JS (1990): Zinc in depressive disorder. Acta Psychiatr Scand 82:451-453.
38. Morimoto A, Murakami N, Nakamori T, Sakata Y, Watanabe T (1989a): Brain regions involved in the development of acute phase responses accompanying fever in rabbits. J Physiol 416:645-657.
39. Morimoto A, Sakata Y, Watanabe T, Murakami N (1989b): Characteristics of fever and acute-phase responses induced in rabbits by IL-1 and TNF. Am J Physiol 256:35-41.
40. Muller N, Ackenheil M, Hofschuster E (1989): Altered T-cell number and reduced suppressor cell activity in patients with affective psychosis. In Hadden JW, Masek K, Nistico G (eds), Interactions among Central Nervous System, Neuroendocrine and Immune Systems. Rome: Pythagora Press, pp 385-394.
41. Muller N, Hofschuster E, Ackenheil M, Mempel W, Eckstein R (1993): Investigations of the cellular immunity during depression and the free interval: Evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry 17:713-730.
42. Mussalo-Rauhamaa H, Konttinen YT, Lehto J, Honkanen V (1988): Predictive clinical and laboratory parameters for serum zinc and copper in rheumatoid arthritis. Ann Rheum Dis 47:816-819.
43. Nassberger L, Traskman-Bendz L (1993): Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatr Scand 88:48-52.
44. Rains TM, Shay NF (1995): Zinc status specifically changes preferences for carbohydrate and protein in rats selecting from separate carbohydrate-, protein-, and fat-containing diets. J Nutr 125:2874-2879.
45. Rea IM (1989): Sex and age changes in serum zinc levels. Nutr Res 9:121-125.
46. Schildkraut JJ (1965): The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 122:509-522.
47. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowiz K (1995): Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann NY Acad Sci 762:474-476.
48. Sluzewska A, Rybakowski JK, Sobieska M, Bosmans E, Pollet H, Wiktorowicz K (in press): Increased levels of alpha-1-acid glycoprotein and interleukin-6 in refractory depression. Depression.
49. Sluzewska A, Rybakowski JK, Sobieska M, Wiktorowicz K (in press): Concentrations and microheterogeneity glycophorms of alpha-1-acid glycoprotein in major depression. J Affect Disord.
50. Sluzewska A, Rybakowski J, Bosmans E, et al (in press): Indicators of immune activation in major depression. Psychiatry Res.
51. Smith RS (1991): The macrophage theory of depression. Med Hypoth 35:298-306.
52. Solomons NW (1988): Zinc and copper. In Shils ME, Young VR (eds), Modern Nutrition in Health and Disease. Philadelphia: Lea & Febiger, pp 238-262.
53. Song C, Dinan T, Leonard BE (1994): Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord 30:283-288.
54. Spitzer RL, Williams JBW, Gibbon M, First MB (1990): Structured Clinical Interview according to DSM-III-R. New York: American Press.
55. Srinivas U, Braconier JH, Jeppsson B, Abdulla M, Akesson B, Ockerman PA (1988): Trace element alterations in infectious diseases. Scand J Clin Lab Invest 48:495-500.
56. Swartz CM (1990): Albumin decrement in depression and cholesterol decrement in mania. J Affect Disord 19:173-176.
57. Thase ME, Rush AJ (1995): Treatment-resistant depression. In Bloom FE, Kupfer DJ (eds), Psychopharmacology, the Fourth Generation of Progress. New York: Raven Press, pp 1081-1098.
58. Van Miert AS, Van Duin CT, Wensing T (1990): Fever and changes in plasma zinc and iron concentrations in the goat. The effects of interferon inducers and recombinant IFN-alpha 2a. J Comp Pathol 103:289-300.
59. Wilson RL (1989): Zinc and iron in free radical pathology and cellular control. In Mills CF (ed), Zinc in Human Biology. London: Springer-Verlag, pp 147-172.
60. Young DS (1993): Effects of Preanalytical Variables on Clinical Laboratory Tests. Hudson, OH: The American Association for Clinical Chemistry Press.
61. Zweig MH, Campbell G (1993): Receiver operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577.